# ITM and POINT Biopharma expand supply agreement for lutetium-177

ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. expanded their global supply agreements for non-carrier-added lutetium-177 (n.c.a. 177Lu) to support POINT's clinical and commercial development. Financial details were not disclosed.

- Type: Contract
- Announced: 2023-07-31
- Status: completed
- Products: n.c.a. lutetium-177

## Companies

- [ITM Isotope Technologies Munich SE](https://endata.com/companies/71728.md) (supplier)
- [POINT Biopharma Global Inc.](https://endata.com/companies/71729.md) (customer)

## Sources

- [itm-radiopharma.com](https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/ITM_and_POINT_Biopharma_Expand_Global_Supply_Agreement_for_n.c.a._Lutetium-177_-658/), 2023-07-31: "The expanded agreement broadens the supply of ITM's non-carrier-added lutetium-177 (n.c.a. 177 Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177 Lu-based molecules in POINT's development pipeline."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.